#Clinicaltrials : Are India’s Ethics Committees weak links in the chain?

Clinical trials, that hot-button subject hogging headlines up until a year ago, appears to have quietly slipped into the realm of business-as-usual. However, there are still some knotty issues to be resolved. Chief among them is the oversight of Ethics Committees (ECs) as was evident at a recent event I attended. ECs - which are … Continue reading #Clinicaltrials : Are India’s Ethics Committees weak links in the chain?

Advertisement

India #Pharma 2014 : A quick look back. Part Two #clinicaltrials #pharmacovigilance

The holiday season approaches, so here’s a quick look at the year that was for Indian Pharma, before we disappear into a haze of year-end festivities. It’s a mixed bag (what year isn’t?) including stuff that could influence the way things work in the years ahead. For convenience, I’ve divided up what I think are … Continue reading India #Pharma 2014 : A quick look back. Part Two #clinicaltrials #pharmacovigilance

Enough said, it’s time to act : my article in PICR

Late last year, I submitted an article to the journal Perspectives in Clinical Research (PICR), brought out by the Indian Society for Clinical Research (ISCR). This issue of PICR is titled "Ethics in Clinical Research" with contributions from bioethicians, patient advocates, trial sponsors and investigators, among others. The publishers informed me yesterday that the issue … Continue reading Enough said, it’s time to act : my article in PICR

Clinical trials in India : Can industry push regulator to act?

A recent meeting that Apothecurry had with clinical research industry executives in Mumbai suggests that the sector intends making a strong push to salvage its tattered image. Faced as it is by an unprecedented crisis of confidence, that's not terribly surprising . However, much of this effort's success will depend on the regulatory reform that … Continue reading Clinical trials in India : Can industry push regulator to act?